Affiliation:
1. Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115
Abstract
ABSTRACT
Integrase inhibitors are emerging anti-human immunodeficiency virus (HIV) drugs, and multiple retroviruses and transposable elements were evaluated here for susceptibilities to raltegravir (RAL) and elvitegravir (EVG). All viruses, including primate and nonprimate lentiviruses, a
Betaretrovirus
, a
Gammaretrovirus
, and the
Alpharetrovirus
Rous sarcoma virus (RSV), were susceptible to inhibition by RAL. EVG potently inhibited all lentiviruses and intermediately inhibited
Betaretrovirus
and
Gammaretrovirus
infections yet was basically ineffective against RSV. Substitutions based on HIV type 1 (HIV-1) resistance changes revealed that integrase residue Ser150 contributed significantly to the resistance of RSV. The drugs intermediately inhibited intracisternal A-particle retrotransposition but were inactive against Sleeping Beauty transposition and long interspersed nucleotide element 1 (LINE-1) retrotransposition.
Publisher
American Society for Microbiology
Subject
Virology,Insect Science,Immunology,Microbiology
Reference54 articles.
1. Beck-Engeser, G. B., D. Eilat, T. Harrer, H. M. Jäck, and M. Wabl. 2009. Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir. Proc. Natl. Acad. Sci. U. S. A. 106:20865-20870.
2. Boeke, J. D., and J. P. Stoye. 1997. Retrotransposons, endogenous retroviruses, and the evolution of retroelements p. 343-435. In J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Plainview, NY.
3. Bouchet, N., et al. 2009. First Mariner Mos1 transposase inhibitors. Mini Rev. Med. Chem. 9:431-439.
4. Chen, Z., et al. 2000. X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293)—an initial glance of the viral DNA binding platform. J. Mol. Biol. 296:521-533.
5. Cooper, D. A., et al. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355-365.
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献